Most Recent Articles by Leah Lawrence
Atezolizumab is the most recent in a line of immune checkpoint inhibitors approved for patients with NSCLC.
Recent research is inconsistent about whether turmeric supplements can prevent and treat cancer.
Cancer Therapy Advisor interviewed Dr Bakal about this new approach to analyzing cell shape and its potential to affect breast cancer treatment.
At an education session at the 2017 GU Symposium experts will discuss some of the barriers to progress in the treatment of bladder cancer.
Genetic factors underlying colorectal cancer (CRC) development may extend beyond those patients with well-known, high-risk features.
More Articles by Leah Lawrence
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Bladder-sparing Therapy Outcomes Similar to Cystectomy in Bladder Cancer
- Prostate Cancer Risk and Fruit Intake
- In Focus: Atezolizumab for Non-small Cell Lung Cancer
- Q&A With Tanya Wildes, MD: Managing Multiple Myeloma in Older Patients
- PSA Density More Accurate Than PSA for Predicting Prostate Cancer
- Everolimus, Exemestane Safety Profile Same With Prior Chemo in Breast Cancer
- Lung Cancer: Timing May Affect EGFR mutation-related ctDNA Test Results
- Adding Bevacizumab to Chemo May Prolong Survival in Recurrent Ovarian Cancer
- Bayesian Adaptive Randomization: A Q&A With Brian M. Alexander MD, PhD
- Lenalidomide Prolongs PFS Among Elderly Patients With DLBCL